Drugs / LY3435151
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04099277 | Oct 2019 → Mar 2020 | cervical carcinoma, gastric adenocarcinoma, head and neck squamous cell carcinoma, hepatocellular carcinoma +4 | Eli Lilly and Company | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY3435151 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04099277 ↗ |
| Route | Intravenous | “Administered IV” NCT04099277 ↗ |